Who are Beyfortus's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): RSVpreF, AREXVY, ABRYSVO, RSV Polyclonal Immunoglobulin, RSVpreF MDV, RSVpreF Vaccine, Abrysvo.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/nirsevimab.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Beyfortus — Competitive Intelligence Brief

Beyfortus (NIRSEVIMAB) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Respiratory Syncytial Virus Anti-F Protein Monoclonal Antibody [EPC]. Area: Infectious Disease.

marketed Respiratory Syncytial Virus Anti-F Protein Monoclonal Antibody [EPC] RSV Infectious Disease Monoclonal antibody Live · refreshed every 30 min

Target snapshot

Beyfortus (NIRSEVIMAB) — AstraZeneca. BEYFORTUS is a monoclonal antibody that targets RSV.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Beyfortus TARGET	NIRSEVIMAB	AstraZeneca	marketed	Respiratory Syncytial Virus Anti-F Protein Monoclonal Antibody [EPC]	RSV	2023-01-01
RSVpreF	rsvpref	Pfizer	marketed	Monoclonal antibody	RSV F protein
AREXVY, ABRYSVO	AREXVY, ABRYSVO	National Heart, Lung, and Blood Institute (NHLBI)	marketed	Recombinant glycoprotein vaccine	RSV fusion (F) glycoprotein, prefusion conformation
RSV Polyclonal Immunoglobulin	RSV Polyclonal Immunoglobulin	National Institute of Allergy and Infectious Diseases (NIAID)	marketed	Polyclonal immunoglobulin	Respiratory syncytial virus (RSV) surface proteins
RSVpreF MDV	rsvpref-mdv	Pfizer Inc.	marketed	Monoclonal antibody	RSV F protein
RSVpreF Vaccine	rsvpref-vaccine	Pfizer Inc.	marketed	vaccine	RSV
Abrysvo	abrysvo	Pfizer	marketed	vaccine	RSV

Recent regulatory actions (last 90 days)

2026-04-07 — Beyfortus · FDA · approved · US · AstraZeneca

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Respiratory Syncytial Virus Anti-F Protein Monoclonal Antibody [EPC] class)

ASTRAZENECA AB · 1 drug in this class
AstraZeneca · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Beyfortus — Competitive Intelligence Brief. https://druglandscape.com/ci/nirsevimab. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab